为醛氧化酶和双醛氧化酶-CYP 底物建立基于生理学的药代动力学框架。

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY CPT: Pharmacometrics & Systems Pharmacology Pub Date : 2024-10-23 DOI:10.1002/psp4.13255
Nihan Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas Valentin, Robert S Jones, Priyanka Kulkarni, Darren Moss, Vincent C Peterkin, Dan-Dan Tian, Andrea Treyer, Karthik Venkatakrishnan, Michael A Zientek, Jill Barber, J Brian Houston, Aleksandra Galetin, Daniel Scotcher
{"title":"为醛氧化酶和双醛氧化酶-CYP 底物建立基于生理学的药代动力学框架。","authors":"Nihan Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas Valentin, Robert S Jones, Priyanka Kulkarni, Darren Moss, Vincent C Peterkin, Dan-Dan Tian, Andrea Treyer, Karthik Venkatakrishnan, Michael A Zientek, Jill Barber, J Brian Houston, Aleksandra Galetin, Daniel Scotcher","doi":"10.1002/psp4.13255","DOIUrl":null,"url":null,"abstract":"<p><p>Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug-metabolizing enzymes such as cytochrome P450s (CYPs). As such, the lack of established framework for quantitative translation of the clinical pharmacologic correlates of AO-mediated clearance represents an unmet need. This study aimed to evaluate the utility of physiologically based pharmacokinetic (PBPK) modeling in the development of AO and dual AO-CYP substrates. PBPK models were developed for capmatinib, idelalisib, lenvatinib, zaleplon, ziprasidone, and zoniporide, incorporating in vitro functional data from human liver subcellular fractions and human hepatocytes. Prediction of metabolic elimination with/without the additional empirical scaling factors (ESFs) was assessed. Clinical pharmacokinetics, human mass balance, and drug-drug interaction (DDI) studies with CYP3A4 modulators, where available, were used to refine/verify the models. Due to the lack of clinically significant AO-DDIs with known AO inhibitors, the fraction metabolized by AO (fm<sub>AO</sub>) was verified indirectly. Clearance predictions were improved by using ESFs (GMFE ≤1.4-fold versus up to fivefold with physiologically-based scaling only). Observed fm<sub>i</sub> from mass balance studies were crucial for model verification/refinement, as illustrated by capmatinib, where the fm<sub>AO</sub> (40%) was otherwise underpredicted up to fourfold. Subsequently, independent DDI studies with ketoconazole, itraconazole, rifampicin, and carbamazepine verified the fm<sub>CYP3A4</sub>, with predicted ratios of the area under the concentration-time curve (AUCR) within 1.5-fold of the observations. In conclusion, this study provides a novel PBPK-based framework for predicting AO-mediated pharmacokinetics and quantitative assessment of clinical DDI risks for dual AO-CYP substrates within a totality-of-evidence approach.</p>","PeriodicalId":10774,"journal":{"name":"CPT: Pharmacometrics & Systems Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates.\",\"authors\":\"Nihan Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas Valentin, Robert S Jones, Priyanka Kulkarni, Darren Moss, Vincent C Peterkin, Dan-Dan Tian, Andrea Treyer, Karthik Venkatakrishnan, Michael A Zientek, Jill Barber, J Brian Houston, Aleksandra Galetin, Daniel Scotcher\",\"doi\":\"10.1002/psp4.13255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug-metabolizing enzymes such as cytochrome P450s (CYPs). As such, the lack of established framework for quantitative translation of the clinical pharmacologic correlates of AO-mediated clearance represents an unmet need. This study aimed to evaluate the utility of physiologically based pharmacokinetic (PBPK) modeling in the development of AO and dual AO-CYP substrates. PBPK models were developed for capmatinib, idelalisib, lenvatinib, zaleplon, ziprasidone, and zoniporide, incorporating in vitro functional data from human liver subcellular fractions and human hepatocytes. Prediction of metabolic elimination with/without the additional empirical scaling factors (ESFs) was assessed. Clinical pharmacokinetics, human mass balance, and drug-drug interaction (DDI) studies with CYP3A4 modulators, where available, were used to refine/verify the models. Due to the lack of clinically significant AO-DDIs with known AO inhibitors, the fraction metabolized by AO (fm<sub>AO</sub>) was verified indirectly. Clearance predictions were improved by using ESFs (GMFE ≤1.4-fold versus up to fivefold with physiologically-based scaling only). Observed fm<sub>i</sub> from mass balance studies were crucial for model verification/refinement, as illustrated by capmatinib, where the fm<sub>AO</sub> (40%) was otherwise underpredicted up to fourfold. Subsequently, independent DDI studies with ketoconazole, itraconazole, rifampicin, and carbamazepine verified the fm<sub>CYP3A4</sub>, with predicted ratios of the area under the concentration-time curve (AUCR) within 1.5-fold of the observations. In conclusion, this study provides a novel PBPK-based framework for predicting AO-mediated pharmacokinetics and quantitative assessment of clinical DDI risks for dual AO-CYP substrates within a totality-of-evidence approach.</p>\",\"PeriodicalId\":10774,\"journal\":{\"name\":\"CPT: Pharmacometrics & Systems Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CPT: Pharmacometrics & Systems Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/psp4.13255\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPT: Pharmacometrics & Systems Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/psp4.13255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

醛氧化酶(AO)有助于清除许多已批准和在研的小分子药物,这些药物通常是 AO 和药物代谢酶(如细胞色素 P450s,CYPs)的双重底物。因此,缺乏对 AO 介导的清除率的临床药理学相关性进行定量转化的既定框架是一项尚未满足的需求。本研究旨在评估基于生理学的药代动力学(PBPK)模型在 AO 和 AO-CYP 双底物开发中的实用性。结合人肝亚细胞组分和人肝细胞的体外功能数据,为卡马替尼、伊德拉利西、来伐替尼、扎来普隆、齐拉西酮和佐尼波利开发了PBPK模型。评估了使用/不使用附加经验缩放因子(ESF)的代谢消除预测。临床药代动力学、人体质量平衡以及与 CYP3A4 调节剂的药物相互作用 (DDI) 研究(如有)被用来完善/验证模型。由于缺乏与已知 AO 抑制剂的具有临床意义的 AO-DDI 研究,因此间接验证了经 AO 代谢的部分(fmAO)。通过使用 ESF,清除率预测得到了改善(GMFE ≤ 1.4 倍,而仅使用基于生理学的缩放比例则高达 5 倍)。质量平衡研究中观察到的 fmi 对模型验证/改进至关重要,卡马替尼就是一例,其 fmAO(40%)被低估了四倍。随后,对酮康唑、伊曲康唑、利福平和卡马西平进行的独立 DDI 研究验证了 fmCYP3A4,预测的浓度-时间曲线下面积(AUCR)比值在观察值的 1.5 倍以内。总之,本研究提供了一种基于 PBPK 的新框架,用于预测 AO 介导的药代动力学,并以证据整体法定量评估 AO-CYP 双底物的临床 DDI 风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates.

Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug-metabolizing enzymes such as cytochrome P450s (CYPs). As such, the lack of established framework for quantitative translation of the clinical pharmacologic correlates of AO-mediated clearance represents an unmet need. This study aimed to evaluate the utility of physiologically based pharmacokinetic (PBPK) modeling in the development of AO and dual AO-CYP substrates. PBPK models were developed for capmatinib, idelalisib, lenvatinib, zaleplon, ziprasidone, and zoniporide, incorporating in vitro functional data from human liver subcellular fractions and human hepatocytes. Prediction of metabolic elimination with/without the additional empirical scaling factors (ESFs) was assessed. Clinical pharmacokinetics, human mass balance, and drug-drug interaction (DDI) studies with CYP3A4 modulators, where available, were used to refine/verify the models. Due to the lack of clinically significant AO-DDIs with known AO inhibitors, the fraction metabolized by AO (fmAO) was verified indirectly. Clearance predictions were improved by using ESFs (GMFE ≤1.4-fold versus up to fivefold with physiologically-based scaling only). Observed fmi from mass balance studies were crucial for model verification/refinement, as illustrated by capmatinib, where the fmAO (40%) was otherwise underpredicted up to fourfold. Subsequently, independent DDI studies with ketoconazole, itraconazole, rifampicin, and carbamazepine verified the fmCYP3A4, with predicted ratios of the area under the concentration-time curve (AUCR) within 1.5-fold of the observations. In conclusion, this study provides a novel PBPK-based framework for predicting AO-mediated pharmacokinetics and quantitative assessment of clinical DDI risks for dual AO-CYP substrates within a totality-of-evidence approach.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.00
自引率
11.40%
发文量
146
审稿时长
8 weeks
期刊最新文献
Clinical study design strategies to mitigate confounding effects of time-dependent clearance on dose optimization of therapeutic antibodies. Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products. Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension. Issue Information Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1